Drawing for MANNKIND

USPTO serial 77383659

MANNKIND

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MARTIN, CHRISTINE C
Law office
DIVISIONAL UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MANNKIND?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marc T. Morley

MARC T. MORLEY KNOBBE MARTENS OLSON & BEAR, LLP2040 MAIN ST FL 14IRVINE, CA 92614-7216UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of allergy, Alzheimer's disease, asthma, autoimmune diseases and disorders, cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, erectile and sexual dysfunction and disorders, gastrointestinal diseases and disorders, gynecological and fertility diseases and disorders, hemolytic diseases and disorders, hormonal diseases and disorders, hypertension, infectious diseases, immunological, bacterial, viral and fungal diseases and disorders, inflammation and inflammatory diseases and disorders, migraines, musculoskeletal diseases and disorders, obesity, ophthalmic and eye diseases and disorders, osteoporosis, pain, Parkinson's disease, psychiatric diseases and disorders, respiratory diseases and disorders, smoking and substance addictions and related diseases and disorders, stroke, urological disorders, weight and appetite controlACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 9, 2012MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 8, 2012ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 9, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 8, 2012EX5GSOU EXTENSION 5 GRANTED—
Mar 7, 2012EXT5SOU EXTENSION 5 FILED—
Mar 7, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 10, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 9, 2011EX4GSOU EXTENSION 4 GRANTED—
Sep 7, 2011EXT4SOU EXTENSION 4 FILED—
Sep 7, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 5, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 4, 2011EX3GSOU EXTENSION 3 GRANTED—
Mar 1, 2011EXT3SOU EXTENSION 3 FILED—
Mar 1, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 16, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 15, 2010EX2GSOU EXTENSION 2 GRANTED—
Sep 7, 2010EXT2SOU EXTENSION 2 FILED—
Sep 7, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 7, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 6, 2010EX1GSOU EXTENSION 1 GRANTED—
Apr 6, 2010DPCCDIVISIONAL PROCESSING COMPLETE—
Apr 2, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 8, 2010EXT1SOU EXTENSION 1 FILED—
Mar 8, 2010DRRRDIVISIONAL REQUEST RECEIVED—
Mar 8, 2010ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Mar 8, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 8, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 16, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2009NPUBNOTICE OF PUBLICATION—
May 12, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 8, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 7, 2009XAECEXAMINER'S AMENDMENT ENTERED—
May 7, 2009GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 7, 2009GNEAEXAMINERS AMENDMENT E-MAILED—
May 7, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 18, 2008DMCCDATA MODIFICATION COMPLETED—
Nov 18, 2008GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 18, 2008GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 18, 2008CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 13, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 12, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 12, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 14, 2008CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
May 14, 2008ALIEASSIGNED TO LIE—
May 14, 2008GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
May 14, 2008GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
May 14, 2008CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
May 7, 2008DOCKASSIGNED TO EXAMINER—
May 7, 2008DOCKASSIGNED TO EXAMINER—
Feb 5, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
Feb 4, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance